NO960607L - Primær og sekundær neurobeskyttende effekt av flupirtin i neurodegenerative sykdommer - Google Patents
Primær og sekundær neurobeskyttende effekt av flupirtin i neurodegenerative sykdommerInfo
- Publication number
- NO960607L NO960607L NO960607A NO960607A NO960607L NO 960607 L NO960607 L NO 960607L NO 960607 A NO960607 A NO 960607A NO 960607 A NO960607 A NO 960607A NO 960607 L NO960607 L NO 960607L
- Authority
- NO
- Norway
- Prior art keywords
- pct
- flupirtine
- primary
- neurodegenerative diseases
- neuroprotective effects
- Prior art date
Links
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003667 flupirtine Drugs 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 231100001018 bone marrow damage Toxicity 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Confectionery (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4327516A DE4327516A1 (de) | 1993-08-17 | 1993-08-17 | Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin |
PCT/EP1994/002649 WO1995005175A1 (en) | 1993-08-17 | 1994-08-10 | The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
NO960607L true NO960607L (no) | 1996-02-15 |
NO960607D0 NO960607D0 (no) | 1996-02-15 |
NO309842B1 NO309842B1 (no) | 2001-04-09 |
Family
ID=6495312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960607A NO309842B1 (no) | 1993-08-17 | 1996-02-15 | Anvendelse av den aktive substansen flupirtin for fremstilling av et medikament for behandling av sykdommer |
Country Status (27)
Country | Link |
---|---|
US (1) | US5721258A (no) |
EP (1) | EP0716602B1 (no) |
JP (1) | JPH09501664A (no) |
KR (1) | KR100341952B1 (no) |
CN (1) | CN1086291C (no) |
AT (1) | ATE210442T1 (no) |
AU (1) | AU694447B2 (no) |
BG (1) | BG62430B1 (no) |
BR (1) | BR9407293A (no) |
CA (1) | CA2169718C (no) |
CZ (1) | CZ289040B6 (no) |
DE (2) | DE4327516A1 (no) |
DK (1) | DK0716602T3 (no) |
EE (1) | EE03204B1 (no) |
ES (1) | ES2168309T3 (no) |
HR (1) | HRP940464A2 (no) |
HU (1) | HU227765B1 (no) |
IL (1) | IL110681A (no) |
NO (1) | NO309842B1 (no) |
NZ (1) | NZ273292A (no) |
PT (1) | PT716602E (no) |
RU (1) | RU2166318C2 (no) |
SK (1) | SK283330B6 (no) |
UA (1) | UA43351C2 (no) |
WO (1) | WO1995005175A1 (no) |
YU (1) | YU49215B (no) |
ZA (1) | ZA946176B (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
DE19541405A1 (de) * | 1995-11-07 | 1997-05-15 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen |
DE19625582A1 (de) * | 1996-06-27 | 1998-01-02 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen |
AU9646298A (en) * | 1997-10-27 | 1999-05-17 | Sumitomo Pharmaceuticals Company, Limited | Amide derivatives |
WO2001034172A2 (en) * | 1999-11-05 | 2001-05-17 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
AU1353901A (en) * | 1999-12-01 | 2001-06-12 | Duke University | Method of treating batten disease |
US6821995B1 (en) | 1999-12-01 | 2004-11-23 | Duke University | Method of treating batten disease |
DE10327674A1 (de) | 2003-06-20 | 2005-01-05 | Awd.Pharma Gmbh & Co. Kg | Injizierbare Darreichungsform von Flupirtin |
DE10328260A1 (de) * | 2003-06-23 | 2005-01-27 | Schmidt, K.-G., Dr. med. | Flupirtine-Präparat |
US8334263B2 (en) * | 2003-12-16 | 2012-12-18 | Raymond Nadeson | Analgesic methods and compositions |
EP1831170A4 (en) * | 2004-12-14 | 2009-10-14 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIDINES AND THEIR USE |
EP1688141A1 (en) | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
US20060258708A1 (en) * | 2005-05-16 | 2006-11-16 | Andrulis Peter J Jr | Method for treating Parkinson's disease and other neurological diseases |
US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
DE102011006425A1 (de) | 2010-03-31 | 2011-10-06 | Awd.Pharma Gmbh & Co. Kg | Pharmazeutische Zubereitung und deren Verwendung |
DE102010030053A1 (de) | 2010-06-14 | 2011-12-15 | Awd.Pharma Gmbh & Co.Kg | Injizierbare Darreichungsform von Flupirtin |
JP2016527270A (ja) * | 2013-07-31 | 2016-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフルピルチンの組合せによる多発性硬化症の治療 |
US11369593B2 (en) * | 2017-07-14 | 2022-06-28 | Texas Tech University System | Functionalized pyridine carbamates with enhanced neuroprotective activity |
DE102017007385A1 (de) | 2017-08-02 | 2019-02-07 | Christoph Hoock | Maleatfreie feste Arzneimittelformen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481205A (en) * | 1980-09-13 | 1984-11-06 | Degussa Aktiengesellschaft | 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate |
EP0110091B1 (de) * | 1982-10-27 | 1987-01-21 | Degussa Aktiengesellschaft | 2-Amino-3-Acylamino-6-benzylamino-pyridin-Derivate mit anti-epileptischer Wirkung |
DE3337593A1 (de) * | 1982-10-27 | 1984-05-03 | Degussa Ag, 6000 Frankfurt | 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung |
NO860825L (no) * | 1985-03-23 | 1986-09-24 | Degussa | Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin. |
IN172468B (no) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag |
-
1993
- 1993-08-17 DE DE4327516A patent/DE4327516A1/de not_active Ceased
-
1994
- 1994-08-10 KR KR1019960700753A patent/KR100341952B1/ko active IP Right Grant
- 1994-08-10 AU AU76528/94A patent/AU694447B2/en not_active Expired
- 1994-08-10 HU HU9600355A patent/HU227765B1/hu unknown
- 1994-08-10 DE DE69429435T patent/DE69429435T2/de not_active Expired - Lifetime
- 1994-08-10 EP EP94926828A patent/EP0716602B1/en not_active Expired - Lifetime
- 1994-08-10 ES ES94926828T patent/ES2168309T3/es not_active Expired - Lifetime
- 1994-08-10 SK SK214-96A patent/SK283330B6/sk not_active IP Right Cessation
- 1994-08-10 US US08/602,742 patent/US5721258A/en not_active Expired - Lifetime
- 1994-08-10 RU RU96105707/14A patent/RU2166318C2/ru active
- 1994-08-10 CZ CZ1996465A patent/CZ289040B6/cs not_active IP Right Cessation
- 1994-08-10 NZ NZ273292A patent/NZ273292A/en not_active IP Right Cessation
- 1994-08-10 WO PCT/EP1994/002649 patent/WO1995005175A1/en active IP Right Grant
- 1994-08-10 CN CN94193106A patent/CN1086291C/zh not_active Expired - Lifetime
- 1994-08-10 AT AT94926828T patent/ATE210442T1/de active
- 1994-08-10 CA CA002169718A patent/CA2169718C/en not_active Expired - Lifetime
- 1994-08-10 JP JP7506731A patent/JPH09501664A/ja active Pending
- 1994-08-10 DK DK94926828T patent/DK0716602T3/da active
- 1994-08-10 PT PT94926828T patent/PT716602E/pt unknown
- 1994-08-10 BR BR9407293A patent/BR9407293A/pt not_active Application Discontinuation
- 1994-08-15 YU YU51294A patent/YU49215B/sh unknown
- 1994-08-16 IL IL11068194A patent/IL110681A/xx not_active IP Right Cessation
- 1994-08-16 HR HRP4327516.8A patent/HRP940464A2/hr not_active Application Discontinuation
- 1994-08-16 ZA ZA946176A patent/ZA946176B/xx unknown
- 1994-10-08 UA UA96030972A patent/UA43351C2/uk unknown
- 1994-10-25 EE EE9400160A patent/EE03204B1/xx unknown
-
1996
- 1996-02-14 BG BG100356A patent/BG62430B1/bg unknown
- 1996-02-15 NO NO960607A patent/NO309842B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO960607L (no) | Primær og sekundær neurobeskyttende effekt av flupirtin i neurodegenerative sykdommer | |
IL111077A0 (en) | Pharmacologically active pyridine derivatives and processes for the preparation thereof | |
HUT71814A (en) | Process for producing pharmaceutical compositions for the treatment of neurological lesions related to traumatic injuries | |
PT703786E (pt) | Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida | |
ZA965235B (en) | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders | |
AU4180593A (en) | The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura | |
NZ271363A (en) | Use of antiglucocorticoid steroids to treat anxiety disorders | |
AU5225498A (en) | Biaromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | |
MX9800049A (es) | Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso. | |
PL312983A1 (en) | Therapeutic preparation | |
HUT77868A (hu) | Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
HU9802142D0 (en) | Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |